[Experimental evaluation of the brucellosis therapeutic vaccine efficacy].
Use of antibiotics can't completely solve the problem of brucellosis treatment, especially its chronic forms, because antibacterial preparations do not eliminate main pathogenetic factor of the disease--sensibilization of the macroorganism. It makes actual the question about complex immuno- and antibacterial therapy. Long-term clinical experience proved high effectiveness of a therapeutic brucellosis vaccine. Earlier this preparation was manufactured in Research Institute of Vaccines and Sera in Tbilisi (Georgia). To date new composition of components of the vaccine has been developed, and manufacturing and control methods have been improved. Marked desensitizing effect of the vaccine and its stimulatory action on cellular and humoral immunity has been observed. In 2002 technological normative documentation for manufacturing and use of the vaccine was developed in the Research Institute of Microbiology (Kirov) and production of the vaccine began.
Shabalin
B A
BA
Okhapkina
V Iu
VIu
Gavrilova
L B
LB
Saiapina
L V
LV
D000373:Agglutinins / Q000097:blood; D000818:Animals; D002004:Brucella Vaccine / Q000008:administration & dosage / Q000302:isolation & purification / Q000592:standards / Q000627:therapeutic use*; D002003:Brucella abortus / Q000254:growth & development / Q000276:immunology*; D017347:Brucella melitensis / Q000254:growth & development / Q000276:immunology*; D002006:Brucellosis / Q000097:blood / Q000276:immunology / Q000628:therapy*; D015925:Cryopreservation; D003470:Culture Media; D004353:Drug Evaluation, Preclinical; D005260:Female; D006168:Guinea Pigs; D007279:Injections, Subcutaneous; D008297:Male; D010587:Phagocytosis
D000373:Agglutinins; D002004:Brucella Vaccine; D003470:Culture Media